Abstract
Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. Representatives of ruthenium-based antitumor drugs are the classes of ruthenium(III)-chlorido-(N-ligand) complexes, including the drugs namely NAMI-A and KP1019 in clinical trials, and ruthenium(II)-arene organometallics, with some compounds currently undergoing advanced preclinical testing. An alternative approach for tumor-inhibiting metallodrugs is the coordination of metal ions to organic pharmaceuticals. The combination of antitumor-active ruthenium ion with biologically-active pro-ligands in single compounds can result in the enhancement of activity, for example through synergistic effects. In the present article, some developments in the ruthenium-based antitumor drugs field are briefly highlighted and recent studies on mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy are described. Novel organic pharmaceuticals-containing diruthenium(II,III) complexes have shown promising antitumor activity for C6 rat glioma - a model for glioblastoma multiforme (GBA).
Keywords: Anticancer activity, antitumor metallodrugs, coordination compounds, glioma, medicinal chemistry, non-steroidal antiinflammatory drugs, ruthenium compounds
Anti-Cancer Agents in Medicinal Chemistry
Title: Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Volume: 10 Issue: 4
Author(s): Denise de Oliveira Silva
Affiliation:
Keywords: Anticancer activity, antitumor metallodrugs, coordination compounds, glioma, medicinal chemistry, non-steroidal antiinflammatory drugs, ruthenium compounds
Abstract: Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. Representatives of ruthenium-based antitumor drugs are the classes of ruthenium(III)-chlorido-(N-ligand) complexes, including the drugs namely NAMI-A and KP1019 in clinical trials, and ruthenium(II)-arene organometallics, with some compounds currently undergoing advanced preclinical testing. An alternative approach for tumor-inhibiting metallodrugs is the coordination of metal ions to organic pharmaceuticals. The combination of antitumor-active ruthenium ion with biologically-active pro-ligands in single compounds can result in the enhancement of activity, for example through synergistic effects. In the present article, some developments in the ruthenium-based antitumor drugs field are briefly highlighted and recent studies on mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy are described. Novel organic pharmaceuticals-containing diruthenium(II,III) complexes have shown promising antitumor activity for C6 rat glioma - a model for glioblastoma multiforme (GBA).
Export Options
About this article
Cite this article as:
de Oliveira Silva Denise, Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (4) . https://dx.doi.org/10.2174/187152010791162333
DOI https://dx.doi.org/10.2174/187152010791162333 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
G-Quadruplex Interacting Agents Targeting the Telomeric G-Overhang Are More than Simple Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics An Artificial Neural Network Model for Predicting the Subcellular Localization of Photosensitisers for Photodynamic Therapy of Solid Tumours
Current Medicinal Chemistry Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Intra-arterial Temozolomide, Osmotic Blood-brain Barrier Disruption and Radiotherapy in a Rat F98-Glioma Model
Clinical Cancer Drugs Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology The Pivotal Role of Multimodality Reporter Sensors in Drug Discovery: From Cell based Assays to Real Time Molecular Imaging
Current Pharmaceutical Biotechnology The Relationship Between Lithium and Cancer Proliferation: A Case-Based Review of the Literature
Current Drug Metabolism The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery Angiomodulatory and Neurological Effects of Ginsenosides
Current Medicinal Chemistry Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Caffeine Effect on HIFs/VEGF Pathway in Human Glioblastoma Cells Exposed to Hypoxia
Anti-Cancer Agents in Medicinal Chemistry The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design